Abstract:Aims:This study aims to investigate and validate the potential drug target to HDAC1.Background:Human histone deacetylase 1 (HDAC1) can catalyze the deacetylation of histones belonging to the family of human histone deacetylases (HDACs). Amide hydrolase HDAC1 plays a key role in the development of many serious cancers such as prostate cancer, gastric cancer, lung cancer, esophageal cancer, colon cancer, and breast cancer. Therefore, HDAC1 inhibitors, promoting the transcription of a series of key genes such as the p53 gene and inhibiting the development of cancer through various downstream mechanisms, have great potential for the treatment of cancer.Objective:The objective of this study is to discover new skeleton HDAC1 inhibitors efficiently and conveniently with therapeutic potential for cancer.Method:Based on the crystal structure of HDAC1, through the combination of receptor-based and ligand- based virtual screening from the commercial compound library, the top-ranked compounds are selected for purchase through binding modes analysis, and their activities were verified through in vitro HDAC1 inhibitory biological experiments.Results:Based on LeDock, 5ICN showed good distinguishing ability and was used as the receptor. According to the results of the LeDock docking scoring from receptor-based virtual screening, 69 compounds with binding energy less than -7.5 kcal/mol were obtained and used for ligand-based virtual screening. A total of 21 novel compounds with high potential HDAC1 inhibitory activity were collected by combining the similarity searching (NN) and the multinomial Naive Bayes machine learning model (NB) methods. Through binding modes analysis, 10 compounds with different structures with potential HDAC1 inhibitory activity were selected and screened HDAC1 inhibitory in vitro. May267 showed moderate HDAC1 inhibitory activity, and the inhibition rate was 48% at a concentration of 20 μM.Conclusion:This study discovers novel small molecule HDAC1 inhibitors by combined receptor-based and ligand-based virtual screening strategy, which provides an efficient method for the discovery of other small molecule drugs. May267 shows moderate HDAC1 inhibitory activity, which can be further optimized as a lead compound. However, it still has the problem of poor kinase selectivity to be solved.

Comparative Modeling and Benchmarking Data Sets for Human Histone Deacetylases and Sirtuin Families

Benchmarking Methods and Data Sets for Ligand Enrichment Assessment in Virtual Screening.

A Thoroughly Validated Virtual Screening Strategy For Discovery Of Novel Hdac3 Inhibitors

Maximal Unbiased Benchmarking Data Sets for Human Chemokine Receptors and Comparative Analysis

The Discovery of Novel HDAC3 Inhibitors Via Virtual Screening and in Vitro Bioassay

MUBD-DecoyMaker 2.0: A Python GUI Application to Generate Maximal Unbiased Benchmarking Data Sets for Virtual Drug Screening

Quantitative Structure-Activity Relationship Study of Histone Deacetylase Inhibitors.

An Unbiased Method to Build Benchmarking Sets for Ligand-Based Virtual Screening and Its Application to GPCRs

Hdac3i-Finder: A Machine Learning-Based Computational Tool To Screen For Hdac3 Inhibitors

Discovery of Novel Small Molecule HDAC1, 2, 3 Inhibitors -- Combined Receptor-Based and Ligand-Based Virtual Screening Strategy

Comparative Structure Based Virtual Screening Utilizing Optimized AlphaFold Model Identifies Selective HDAC11 Inhibitor

Comparative Structure-Based Virtual Screening Utilizing Optimized AlphaFold Model Identifies Selective HDAC11 Inhibitor

Homology modeling and in silico design of novel and potential dual-acting inhibitors of human histone deacetylases HDAC5 and HDAC9 isozymes

Structure-Based Identification of Novel Histone Deacetylase 4 (HDAC4) Inhibitors

Screening of Selective Histone Deacetylase Inhibitors by Proteochemometric Modeling

3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment.

Identification of novel leads as potent inhibitors of HDAC3 using ligand-based pharmacophore modeling and MD simulation

Design, Synthesis and Biological Evaluation of Novel Histone Deacetylase Inhibitors Based on Virtual Screening

Stack-HDAC3i: A high-precision identification of HDAC3 inhibitors by exploiting a stacked ensemble-learning framework

Structure-based discovery of selective histone deacetylase (HDAC) 3 and 4 inhibitors

Development of Novel Hydroxy Amide‐Based HDAC1 Inhibitors: Integrated Pharmacophore Modelling, 3D‐QSAR, and Virtual Screening Studies